Mouse endostatin inhibits the formation of lung and liver metastases.
Angiogenesis is required for tumor formation. Several studies have demonstrated that tumor angiogenesis is regulated by a balance between proangiogenesis and antiangiogenesis factors and that this balance varies in different organ environments. To investigate whether expression of an angiogenesis inhibitor by cancer cells could alter this balance and prevent tumor formation in different organ environments, we engineered stable transfectants from RenCa mouse renal carcinoma cells and SW620 human colon carcinoma cells to constitutively secrete a mouse endostatin protein with c-myc and polyhistidine (His) tags. Production and secretion of the endostatin-c-myc-His fusion protein by endostatin-transfected cells were confirmed by immunofluorescence staining and Western blot analysis. The endostatin transfectants and control transfectants, stably transfected with a control plasmid, had similar in vitro growth rates compared with their parental cell lines. Conditioned medium from endostatin-transfected cells inhibited human umbilical vein endothelial cell proliferation by 36-51% compared with conditioned medium from control cells. After inoculation into mice, flank tumors from endostatin-transfected cells were 73-91% smaller than flank tumors from control cells after 3 weeks. Inoculation of a cell mixture containing 25% endostatin-transfected cells and 75% control cells resulted in inhibition of flank tumor formation as effective as after inoculation of 100% endostatin-transfected cells. Formation of lung metastases by RenCa endostatin-transfected cells and formation of liver metastases by SW620 endostatin-transfected cells were dramatically inhibited compared with formation of metastases by control cells. These findings demonstrate that endostatin can inhibit tumor formation in different organ environments and that gene delivery of endostatin into even a minority of tumor cells may be an effective strategy to prevent progression of micrometastases to macroscopic disease.
Yoon
S S
SS
Department of Surgery, Massachusetts General Hospital, and Harvard Medical School, Boston 02114, USA.
Eto
H
H
Lin
C M
CM
Nakamura
H
H
Pawlik
T M
TM
Song
S U
SU
Tanabe
K K
KK
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002455:Cell Division / Q000187:drug effects; D003094:Collagen / Q000235:genetics / Q000627:therapeutic use*; D043169:Endostatins; D004730:Endothelium, Vascular / Q000187:drug effects; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology / Q000517:prevention & control*; D008175:Lung Neoplasms / Q000473:pathology / Q000517:prevention & control*; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009362:Neoplasm Metastasis / Q000517:prevention & control*; D010446:Peptide Fragments / Q000235:genetics / Q000627:therapeutic use*; D014162:Transfection; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D043169:Endostatins; D010446:Peptide Fragments; D003094:Collagen